Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

Bräu N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, Cheung RC, Hu KQ, Anand BS, Simon FR, Aytaman A, Johnson DP, Awad JA, Ahmad J, Mendenhall CL, Pedrosa MC, Moseley RH, Hagedorn CH, Waters B, Chang KM, Morgan TR, Rossi SJ, Jeffers LJ, Wright TL; VA-HCV-001 Study Group..

J Viral Hepat. 2006 Apr;13(4):242-9.

PMID:
16611190
2.
3.

Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.

Fargion S, Bruno S, Borzio M, Battezzati PM, Bissoli F, Ceriani R, Orlandi A, Maraschi A, Chiesa A, Morini L, Fracanzani AL, Crosignani A, Fiorelli G, Podda M.

J Hepatol. 2003 Apr;38(4):499-505.

PMID:
12663243
4.
5.

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

Wartelle-Bladou C, Arpurt JP, Renou C, Pariente A, Pillon D, Nalet B, Picon M, Glibert A, Chousterman M, Grasset D, Morin T, Bernard P, Fischer D, Ramdani M, Lagier E, Rotily M; Viral Hepatitis Group of the ANGH..

Gastroenterol Clin Biol. 2006 Apr;30(4):525-32.

6.

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.

Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT.

Transl Res. 2006 Sep;148(3):120-7.

PMID:
16938649
7.

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R.

J Viral Hepat. 2004 May;11(3):243-50.

PMID:
15117326
8.

Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.

Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN.

Am J Gastroenterol. 2008 Mar;103(3):605-14. doi: 10.1111/j.1572-0241.2007.01729.x. Epub 2008 Jan 8.

PMID:
18190648
9.

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.

Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS.

Am J Gastroenterol. 2003 Nov;98(11):2491-9.

PMID:
14638354
10.
11.

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon.

Cozzolongo R, Cuppone R, Giannuzzi V, Amati L, Caradonna L, Tamborrino V, Jirillo E, Manghisi OG.

Aliment Pharmacol Ther. 2001 Jan;15(1):129-35.

12.

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.

Moreno-Monteagudo JA, Castro A, De Pedro A, Lorenzo JA, Fernández-Bermejo M, Lopez S, García-Buey L, Borque MJ, Pedreira JD, Moreno-Otero R.

Aliment Pharmacol Ther. 2002 Feb;16(2):243-9.

13.

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen DS, Brouwer JT.

Gastroenterology. 1999 Aug;117(2):408-13.

PMID:
10419923
14.

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML.

J Hepatol. 2012 Jan;56(1):34-40. doi: 10.1016/j.jhep.2011.03.029. Epub 2011 May 19. Erratum in: J Hepatol. 2012 May;56(5):1218.

PMID:
21703176
15.

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

Böcher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Löhr HF, Galle PR.

Liver Int. 2006 Apr;26(3):319-25.

PMID:
16584394
16.

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone.

Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni MC, Cristini G, Rossi S, Spinetti A, Zaltron S, Zanini B, Quiros-Roldan E, Paraninfo G, Gargiulo F, Carosi G.

Dig Liver Dis. 2001 Mar;33(2):163-72.

PMID:
11346146
17.

Ribavirin in the treatment of hepatitis C.

Abonyi ME, Lakatos PL.

Anticancer Res. 2005 Mar-Apr;25(2B):1315-20.

18.
19.

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; B2202 Study Team..

J Viral Hepat. 2012 Sep;19(9):623-34. doi: 10.1111/j.1365-2893.2012.01586.x. Epub 2012 Mar 21.

PMID:
22863266
20.

Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.

Cheng PN, Chow NH, Hu SC, Young KC, Chen CY, Jen CM, Chang TT.

Dig Liver Dis. 2002 Dec;34(12):851-6.

PMID:
12643293

Supplemental Content

Support Center